nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobunolol—Rash generalised—Sunitinib—pancreatic cancer	0.0255	0.0312	CcSEcCtD
Levobunolol—Keratitis—Erlotinib—pancreatic cancer	0.0193	0.0236	CcSEcCtD
Levobunolol—Rash generalised—Docetaxel—pancreatic cancer	0.0145	0.0178	CcSEcCtD
Levobunolol—Respiratory failure—Sunitinib—pancreatic cancer	0.011	0.0135	CcSEcCtD
Levobunolol—Stinging—Fluorouracil—pancreatic cancer	0.0105	0.0129	CcSEcCtD
Levobunolol—Visual disturbance—Tamoxifen—pancreatic cancer	0.00968	0.0119	CcSEcCtD
Levobunolol—Cerebrovascular accident—Erlotinib—pancreatic cancer	0.00926	0.0114	CcSEcCtD
Levobunolol—Respiratory failure—Gemcitabine—pancreatic cancer	0.00884	0.0108	CcSEcCtD
Levobunolol—Cardiac failure congestive—Sunitinib—pancreatic cancer	0.00866	0.0106	CcSEcCtD
Levobunolol—Nasal congestion—Sunitinib—pancreatic cancer	0.00862	0.0106	CcSEcCtD
Levobunolol—Hypoglycaemia—Sunitinib—pancreatic cancer	0.00805	0.00987	CcSEcCtD
Levobunolol—Cerebrovascular accident—Sunitinib—pancreatic cancer	0.00802	0.00983	CcSEcCtD
Levobunolol—Erectile dysfunction—Tamoxifen—pancreatic cancer	0.0073	0.00895	CcSEcCtD
Levobunolol—Depression—Tamoxifen—pancreatic cancer	0.00705	0.00864	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Tamoxifen—pancreatic cancer	0.00701	0.00859	CcSEcCtD
Levobunolol—Depression—Erlotinib—pancreatic cancer	0.00697	0.00855	CcSEcCtD
Levobunolol—Cardiac failure congestive—Gemcitabine—pancreatic cancer	0.00695	0.00852	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Erlotinib—pancreatic cancer	0.00693	0.0085	CcSEcCtD
Levobunolol—Visual disturbance—Irinotecan—pancreatic cancer	0.00683	0.00837	CcSEcCtD
Levobunolol—Conjunctivitis—Erlotinib—pancreatic cancer	0.0068	0.00834	CcSEcCtD
Levobunolol—Cerebrovascular accident—Irinotecan—pancreatic cancer	0.0066	0.0081	CcSEcCtD
Levobunolol—Cerebrovascular accident—Gemcitabine—pancreatic cancer	0.00643	0.00789	CcSEcCtD
Levobunolol—Keratitis—Epirubicin—pancreatic cancer	0.00641	0.00786	CcSEcCtD
Levobunolol—Lethargy—Fluorouracil—pancreatic cancer	0.00632	0.00776	CcSEcCtD
Levobunolol—Respiratory failure—Docetaxel—pancreatic cancer	0.00628	0.0077	CcSEcCtD
Levobunolol—Cardiac arrest—Irinotecan—pancreatic cancer	0.00615	0.00755	CcSEcCtD
Levobunolol—Visual impairment—Tamoxifen—pancreatic cancer	0.00611	0.0075	CcSEcCtD
Levobunolol—Depression—Sunitinib—pancreatic cancer	0.00604	0.0074	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Sunitinib—pancreatic cancer	0.006	0.00736	CcSEcCtD
Levobunolol—Erythema multiforme—Tamoxifen—pancreatic cancer	0.006	0.00736	CcSEcCtD
Levobunolol—Erythema multiforme—Erlotinib—pancreatic cancer	0.00594	0.00728	CcSEcCtD
Levobunolol—Keratitis—Doxorubicin—pancreatic cancer	0.00593	0.00727	CcSEcCtD
Levobunolol—Cardiac arrest—Fluorouracil—pancreatic cancer	0.00589	0.00723	CcSEcCtD
Levobunolol—Ataxia—Fluorouracil—pancreatic cancer	0.00583	0.00715	CcSEcCtD
Levobunolol—Arrhythmia—Tamoxifen—pancreatic cancer	0.00567	0.00695	CcSEcCtD
Levobunolol—Arrhythmia—Erlotinib—pancreatic cancer	0.00561	0.00688	CcSEcCtD
Levobunolol—Alopecia—Tamoxifen—pancreatic cancer	0.00561	0.00688	CcSEcCtD
Levobunolol—Alopecia—Erlotinib—pancreatic cancer	0.00555	0.0068	CcSEcCtD
Levobunolol—Bradycardia—Sunitinib—pancreatic cancer	0.00553	0.00678	CcSEcCtD
Levobunolol—Bronchospasm—Gemcitabine—pancreatic cancer	0.00536	0.00657	CcSEcCtD
Levobunolol—Erythema multiforme—Sunitinib—pancreatic cancer	0.00514	0.0063	CcSEcCtD
Levobunolol—Stinging—Epirubicin—pancreatic cancer	0.00513	0.00629	CcSEcCtD
Levobunolol—Cardiac failure congestive—Docetaxel—pancreatic cancer	0.00493	0.00605	CcSEcCtD
Levobunolol—Syncope—Erlotinib—pancreatic cancer	0.0049	0.00601	CcSEcCtD
Levobunolol—Arrhythmia—Sunitinib—pancreatic cancer	0.00485	0.00595	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Gemcitabine—pancreatic cancer	0.00482	0.00591	CcSEcCtD
Levobunolol—Loss of consciousness—Erlotinib—pancreatic cancer	0.0048	0.00589	CcSEcCtD
Levobunolol—Alopecia—Sunitinib—pancreatic cancer	0.0048	0.00589	CcSEcCtD
Levobunolol—Stinging—Doxorubicin—pancreatic cancer	0.00475	0.00582	CcSEcCtD
Levobunolol—Visual disturbance—Docetaxel—pancreatic cancer	0.00472	0.00579	CcSEcCtD
Levobunolol—Chest pain—Tamoxifen—pancreatic cancer	0.0047	0.00577	CcSEcCtD
Levobunolol—Chest pain—Erlotinib—pancreatic cancer	0.00465	0.00571	CcSEcCtD
Levobunolol—Conjunctivitis—Fluorouracil—pancreatic cancer	0.00464	0.00569	CcSEcCtD
Levobunolol—Lethargy—Docetaxel—pancreatic cancer	0.00456	0.0056	CcSEcCtD
Levobunolol—Bradycardia—Irinotecan—pancreatic cancer	0.00456	0.00559	CcSEcCtD
Levobunolol—Shock—Erlotinib—pancreatic cancer	0.00439	0.00538	CcSEcCtD
Levobunolol—Visual impairment—Irinotecan—pancreatic cancer	0.00431	0.00529	CcSEcCtD
Levobunolol—Atrioventricular block—Epirubicin—pancreatic cancer	0.00428	0.00526	CcSEcCtD
Levobunolol—Ataxia—Docetaxel—pancreatic cancer	0.00421	0.00516	CcSEcCtD
Levobunolol—Erythema multiforme—Gemcitabine—pancreatic cancer	0.00412	0.00506	CcSEcCtD
Levobunolol—Paraesthesia—Tamoxifen—pancreatic cancer	0.00405	0.00496	CcSEcCtD
Levobunolol—Chest pain—Sunitinib—pancreatic cancer	0.00403	0.00494	CcSEcCtD
Levobunolol—Dyspnoea—Tamoxifen—pancreatic cancer	0.00402	0.00493	CcSEcCtD
Levobunolol—Arrhythmia—Irinotecan—pancreatic cancer	0.004	0.0049	CcSEcCtD
Levobunolol—Dyspnoea—Erlotinib—pancreatic cancer	0.00398	0.00488	CcSEcCtD
Levobunolol—Atrioventricular block—Doxorubicin—pancreatic cancer	0.00396	0.00486	CcSEcCtD
Levobunolol—Alopecia—Irinotecan—pancreatic cancer	0.00396	0.00485	CcSEcCtD
Levobunolol—Arrhythmia—Gemcitabine—pancreatic cancer	0.0039	0.00478	CcSEcCtD
Levobunolol—Pain—Tamoxifen—pancreatic cancer	0.00385	0.00473	CcSEcCtD
Levobunolol—Alopecia—Gemcitabine—pancreatic cancer	0.00385	0.00473	CcSEcCtD
Levobunolol—Arrhythmia—Fluorouracil—pancreatic cancer	0.00383	0.0047	CcSEcCtD
Levobunolol—Pain—Erlotinib—pancreatic cancer	0.00381	0.00468	CcSEcCtD
Levobunolol—Bronchospasm—Docetaxel—pancreatic cancer	0.0038	0.00466	CcSEcCtD
Levobunolol—Shock—Sunitinib—pancreatic cancer	0.0038	0.00466	CcSEcCtD
Levobunolol—Alopecia—Fluorouracil—pancreatic cancer	0.00379	0.00465	CcSEcCtD
Levobunolol—Urticaria—Tamoxifen—pancreatic cancer	0.00358	0.00439	CcSEcCtD
Levobunolol—Syncope—Irinotecan—pancreatic cancer	0.00349	0.00429	CcSEcCtD
Levobunolol—Diabetes mellitus—Epirubicin—pancreatic cancer	0.00347	0.00425	CcSEcCtD
Levobunolol—Paraesthesia—Sunitinib—pancreatic cancer	0.00347	0.00425	CcSEcCtD
Levobunolol—Dyspnoea—Sunitinib—pancreatic cancer	0.00344	0.00422	CcSEcCtD
Levobunolol—Loss of consciousness—Irinotecan—pancreatic cancer	0.00342	0.0042	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.00342	0.00419	CcSEcCtD
Levobunolol—Conjunctivitis—Docetaxel—pancreatic cancer	0.00335	0.00411	CcSEcCtD
Levobunolol—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.00333	0.00408	CcSEcCtD
Levobunolol—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00332	0.00407	CcSEcCtD
Levobunolol—Pain—Sunitinib—pancreatic cancer	0.0033	0.00405	CcSEcCtD
Levobunolol—Asthenia—Tamoxifen—pancreatic cancer	0.00323	0.00397	CcSEcCtD
Levobunolol—Chest pain—Gemcitabine—pancreatic cancer	0.00323	0.00396	CcSEcCtD
Levobunolol—Diabetes mellitus—Doxorubicin—pancreatic cancer	0.00321	0.00394	CcSEcCtD
Levobunolol—Confusional state—Irinotecan—pancreatic cancer	0.00321	0.00393	CcSEcCtD
Levobunolol—Asthenia—Erlotinib—pancreatic cancer	0.0032	0.00392	CcSEcCtD
Levobunolol—Pruritus—Tamoxifen—pancreatic cancer	0.00319	0.00391	CcSEcCtD
Levobunolol—Chest pain—Fluorouracil—pancreatic cancer	0.00318	0.0039	CcSEcCtD
Levobunolol—Pruritus—Erlotinib—pancreatic cancer	0.00316	0.00387	CcSEcCtD
Levobunolol—Shock—Irinotecan—pancreatic cancer	0.00313	0.00384	CcSEcCtD
Levobunolol—Hypoglycaemia—Epirubicin—pancreatic cancer	0.00309	0.00379	CcSEcCtD
Levobunolol—Diarrhoea—Tamoxifen—pancreatic cancer	0.00308	0.00378	CcSEcCtD
Levobunolol—Lethargy—Epirubicin—pancreatic cancer	0.00308	0.00378	CcSEcCtD
Levobunolol—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.00308	0.00378	CcSEcCtD
Levobunolol—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.00308	0.00378	CcSEcCtD
Levobunolol—Confusional state—Fluorouracil—pancreatic cancer	0.00307	0.00377	CcSEcCtD
Levobunolol—Diarrhoea—Erlotinib—pancreatic cancer	0.00305	0.00374	CcSEcCtD
Levobunolol—Diplopia—Epirubicin—pancreatic cancer	0.00302	0.0037	CcSEcCtD
Levobunolol—Visual impairment—Docetaxel—pancreatic cancer	0.00298	0.00366	CcSEcCtD
Levobunolol—Dizziness—Tamoxifen—pancreatic cancer	0.00298	0.00366	CcSEcCtD
Levobunolol—Hypotension—Irinotecan—pancreatic cancer	0.00297	0.00364	CcSEcCtD
Levobunolol—Dizziness—Erlotinib—pancreatic cancer	0.00295	0.00362	CcSEcCtD
Levobunolol—Erythema multiforme—Docetaxel—pancreatic cancer	0.00293	0.00359	CcSEcCtD
Levobunolol—Hypotension—Gemcitabine—pancreatic cancer	0.00289	0.00355	CcSEcCtD
Levobunolol—Cardiac arrest—Epirubicin—pancreatic cancer	0.00287	0.00352	CcSEcCtD
Levobunolol—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.00286	0.00351	CcSEcCtD
Levobunolol—Paraesthesia—Irinotecan—pancreatic cancer	0.00286	0.0035	CcSEcCtD
Levobunolol—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.00285	0.00349	CcSEcCtD
Levobunolol—Lethargy—Doxorubicin—pancreatic cancer	0.00285	0.00349	CcSEcCtD
Levobunolol—Hypotension—Fluorouracil—pancreatic cancer	0.00285	0.00349	CcSEcCtD
Levobunolol—Hypersensitivity—Sunitinib—pancreatic cancer	0.00284	0.00349	CcSEcCtD
Levobunolol—Ataxia—Epirubicin—pancreatic cancer	0.00284	0.00348	CcSEcCtD
Levobunolol—Dyspnoea—Irinotecan—pancreatic cancer	0.00284	0.00348	CcSEcCtD
Levobunolol—Headache—Tamoxifen—pancreatic cancer	0.00282	0.00346	CcSEcCtD
Levobunolol—Headache—Erlotinib—pancreatic cancer	0.00279	0.00343	CcSEcCtD
Levobunolol—Diplopia—Doxorubicin—pancreatic cancer	0.00279	0.00342	CcSEcCtD
Levobunolol—Paraesthesia—Gemcitabine—pancreatic cancer	0.00278	0.00341	CcSEcCtD
Levobunolol—Asthenia—Sunitinib—pancreatic cancer	0.00277	0.0034	CcSEcCtD
Levobunolol—Arrhythmia—Docetaxel—pancreatic cancer	0.00276	0.00339	CcSEcCtD
Levobunolol—Dyspnoea—Gemcitabine—pancreatic cancer	0.00276	0.00339	CcSEcCtD
Levobunolol—Paraesthesia—Fluorouracil—pancreatic cancer	0.00274	0.00335	CcSEcCtD
Levobunolol—Alopecia—Docetaxel—pancreatic cancer	0.00273	0.00335	CcSEcCtD
Levobunolol—Pruritus—Sunitinib—pancreatic cancer	0.00273	0.00335	CcSEcCtD
Levobunolol—Pain—Irinotecan—pancreatic cancer	0.00272	0.00334	CcSEcCtD
Levobunolol—Dyspnoea—Fluorouracil—pancreatic cancer	0.00272	0.00333	CcSEcCtD
Levobunolol—Nausea—Tamoxifen—pancreatic cancer	0.00268	0.00328	CcSEcCtD
Levobunolol—Cardiac arrest—Doxorubicin—pancreatic cancer	0.00265	0.00326	CcSEcCtD
Levobunolol—Pain—Gemcitabine—pancreatic cancer	0.00265	0.00325	CcSEcCtD
Levobunolol—Nausea—Erlotinib—pancreatic cancer	0.00265	0.00325	CcSEcCtD
Levobunolol—Diarrhoea—Sunitinib—pancreatic cancer	0.00264	0.00324	CcSEcCtD
Levobunolol—Ataxia—Doxorubicin—pancreatic cancer	0.00262	0.00322	CcSEcCtD
Levobunolol—Feeling abnormal—Irinotecan—pancreatic cancer	0.00262	0.00321	CcSEcCtD
Levobunolol—Pain—Fluorouracil—pancreatic cancer	0.0026	0.00319	CcSEcCtD
Levobunolol—Dizziness—Sunitinib—pancreatic cancer	0.00255	0.00313	CcSEcCtD
Levobunolol—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00255	0.00313	CcSEcCtD
Levobunolol—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00251	0.00308	CcSEcCtD
Levobunolol—Urticaria—Fluorouracil—pancreatic cancer	0.00242	0.00297	CcSEcCtD
Levobunolol—Headache—Sunitinib—pancreatic cancer	0.00242	0.00297	CcSEcCtD
Levobunolol—Syncope—Docetaxel—pancreatic cancer	0.00242	0.00296	CcSEcCtD
Levobunolol—Palpitations—Docetaxel—pancreatic cancer	0.00238	0.00292	CcSEcCtD
Levobunolol—Loss of consciousness—Docetaxel—pancreatic cancer	0.00237	0.0029	CcSEcCtD
Levobunolol—Hypersensitivity—Irinotecan—pancreatic cancer	0.00234	0.00287	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.00231	0.00283	CcSEcCtD
Levobunolol—Chest pain—Docetaxel—pancreatic cancer	0.00229	0.00281	CcSEcCtD
Levobunolol—Nausea—Sunitinib—pancreatic cancer	0.00229	0.00281	CcSEcCtD
Levobunolol—Asthenia—Irinotecan—pancreatic cancer	0.00228	0.0028	CcSEcCtD
Levobunolol—Conjunctivitis—Epirubicin—pancreatic cancer	0.00226	0.00277	CcSEcCtD
Levobunolol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00224	0.00275	CcSEcCtD
Levobunolol—Asthenia—Gemcitabine—pancreatic cancer	0.00222	0.00273	CcSEcCtD
Levobunolol—Confusional state—Docetaxel—pancreatic cancer	0.00222	0.00272	CcSEcCtD
Levobunolol—Pruritus—Gemcitabine—pancreatic cancer	0.00219	0.00269	CcSEcCtD
Levobunolol—Diarrhoea—Irinotecan—pancreatic cancer	0.00218	0.00267	CcSEcCtD
Levobunolol—Shock—Docetaxel—pancreatic cancer	0.00216	0.00265	CcSEcCtD
Levobunolol—Pruritus—Fluorouracil—pancreatic cancer	0.00216	0.00264	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.00213	0.00262	CcSEcCtD
Levobunolol—Bradycardia—Epirubicin—pancreatic cancer	0.00212	0.00261	CcSEcCtD
Levobunolol—Diarrhoea—Gemcitabine—pancreatic cancer	0.00212	0.0026	CcSEcCtD
Levobunolol—Dizziness—Irinotecan—pancreatic cancer	0.0021	0.00258	CcSEcCtD
Levobunolol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00209	0.00256	CcSEcCtD
Levobunolol—Diarrhoea—Fluorouracil—pancreatic cancer	0.00208	0.00256	CcSEcCtD
Levobunolol—Hypotension—Docetaxel—pancreatic cancer	0.00205	0.00252	CcSEcCtD
Levobunolol—Dizziness—Fluorouracil—pancreatic cancer	0.00201	0.00247	CcSEcCtD
Levobunolol—Visual impairment—Epirubicin—pancreatic cancer	0.00201	0.00247	CcSEcCtD
Levobunolol—Headache—Irinotecan—pancreatic cancer	0.00199	0.00244	CcSEcCtD
Levobunolol—Paraesthesia—Docetaxel—pancreatic cancer	0.00197	0.00242	CcSEcCtD
Levobunolol—Erythema multiforme—Epirubicin—pancreatic cancer	0.00197	0.00242	CcSEcCtD
Levobunolol—Bradycardia—Doxorubicin—pancreatic cancer	0.00197	0.00241	CcSEcCtD
Levobunolol—Dyspnoea—Docetaxel—pancreatic cancer	0.00196	0.0024	CcSEcCtD
Levobunolol—Headache—Gemcitabine—pancreatic cancer	0.00194	0.00238	CcSEcCtD
Levobunolol—Headache—Fluorouracil—pancreatic cancer	0.00191	0.00234	CcSEcCtD
Levobunolol—Nausea—Irinotecan—pancreatic cancer	0.00189	0.00232	CcSEcCtD
Levobunolol—Pain—Docetaxel—pancreatic cancer	0.00188	0.00231	CcSEcCtD
Levobunolol—Arrhythmia—Epirubicin—pancreatic cancer	0.00186	0.00229	CcSEcCtD
Levobunolol—Visual impairment—Doxorubicin—pancreatic cancer	0.00186	0.00228	CcSEcCtD
Levobunolol—Alopecia—Epirubicin—pancreatic cancer	0.00184	0.00226	CcSEcCtD
Levobunolol—Nausea—Gemcitabine—pancreatic cancer	0.00184	0.00226	CcSEcCtD
Levobunolol—Erythema multiforme—Doxorubicin—pancreatic cancer	0.00183	0.00224	CcSEcCtD
Levobunolol—Feeling abnormal—Docetaxel—pancreatic cancer	0.00181	0.00222	CcSEcCtD
Levobunolol—Nausea—Fluorouracil—pancreatic cancer	0.00181	0.00222	CcSEcCtD
Levobunolol—Arrhythmia—Doxorubicin—pancreatic cancer	0.00173	0.00212	CcSEcCtD
Levobunolol—Alopecia—Doxorubicin—pancreatic cancer	0.00171	0.00209	CcSEcCtD
Levobunolol—Syncope—Epirubicin—pancreatic cancer	0.00163	0.002	CcSEcCtD
Levobunolol—Hypersensitivity—Docetaxel—pancreatic cancer	0.00162	0.00199	CcSEcCtD
Levobunolol—Palpitations—Epirubicin—pancreatic cancer	0.00161	0.00197	CcSEcCtD
Levobunolol—Loss of consciousness—Epirubicin—pancreatic cancer	0.0016	0.00196	CcSEcCtD
Levobunolol—Asthenia—Docetaxel—pancreatic cancer	0.00158	0.00193	CcSEcCtD
Levobunolol—Pruritus—Docetaxel—pancreatic cancer	0.00156	0.00191	CcSEcCtD
Levobunolol—Chest pain—Epirubicin—pancreatic cancer	0.00155	0.0019	CcSEcCtD
Levobunolol—Syncope—Doxorubicin—pancreatic cancer	0.00151	0.00185	CcSEcCtD
Levobunolol—Diarrhoea—Docetaxel—pancreatic cancer	0.0015	0.00184	CcSEcCtD
Levobunolol—Confusional state—Epirubicin—pancreatic cancer	0.0015	0.00183	CcSEcCtD
Levobunolol—Palpitations—Doxorubicin—pancreatic cancer	0.00149	0.00182	CcSEcCtD
Levobunolol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.00148	0.00181	CcSEcCtD
Levobunolol—Shock—Epirubicin—pancreatic cancer	0.00146	0.00179	CcSEcCtD
Levobunolol—Dizziness—Docetaxel—pancreatic cancer	0.00145	0.00178	CcSEcCtD
Levobunolol—Chest pain—Doxorubicin—pancreatic cancer	0.00143	0.00176	CcSEcCtD
Levobunolol—Hypotension—Epirubicin—pancreatic cancer	0.00139	0.0017	CcSEcCtD
Levobunolol—Confusional state—Doxorubicin—pancreatic cancer	0.00138	0.0017	CcSEcCtD
Levobunolol—Headache—Docetaxel—pancreatic cancer	0.00138	0.00169	CcSEcCtD
Levobunolol—Shock—Doxorubicin—pancreatic cancer	0.00135	0.00166	CcSEcCtD
Levobunolol—Paraesthesia—Epirubicin—pancreatic cancer	0.00133	0.00163	CcSEcCtD
Levobunolol—Dyspnoea—Epirubicin—pancreatic cancer	0.00132	0.00162	CcSEcCtD
Levobunolol—Nausea—Docetaxel—pancreatic cancer	0.00131	0.0016	CcSEcCtD
Levobunolol—Hypotension—Doxorubicin—pancreatic cancer	0.00128	0.00157	CcSEcCtD
Levobunolol—Pain—Epirubicin—pancreatic cancer	0.00127	0.00156	CcSEcCtD
Levobunolol—Paraesthesia—Doxorubicin—pancreatic cancer	0.00123	0.00151	CcSEcCtD
Levobunolol—Dyspnoea—Doxorubicin—pancreatic cancer	0.00122	0.0015	CcSEcCtD
Levobunolol—Feeling abnormal—Epirubicin—pancreatic cancer	0.00122	0.0015	CcSEcCtD
Levobunolol—Urticaria—Epirubicin—pancreatic cancer	0.00118	0.00144	CcSEcCtD
Levobunolol—Pain—Doxorubicin—pancreatic cancer	0.00117	0.00144	CcSEcCtD
Levobunolol—Feeling abnormal—Doxorubicin—pancreatic cancer	0.00113	0.00139	CcSEcCtD
Levobunolol—Hypersensitivity—Epirubicin—pancreatic cancer	0.00109	0.00134	CcSEcCtD
Levobunolol—Urticaria—Doxorubicin—pancreatic cancer	0.00109	0.00134	CcSEcCtD
Levobunolol—Asthenia—Epirubicin—pancreatic cancer	0.00106	0.0013	CcSEcCtD
Levobunolol—Pruritus—Epirubicin—pancreatic cancer	0.00105	0.00129	CcSEcCtD
Levobunolol—Diarrhoea—Epirubicin—pancreatic cancer	0.00101	0.00124	CcSEcCtD
Levobunolol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00101	0.00124	CcSEcCtD
Levobunolol—Asthenia—Doxorubicin—pancreatic cancer	0.000984	0.00121	CcSEcCtD
Levobunolol—Dizziness—Epirubicin—pancreatic cancer	0.000981	0.0012	CcSEcCtD
Levobunolol—Pruritus—Doxorubicin—pancreatic cancer	0.000971	0.00119	CcSEcCtD
Levobunolol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000939	0.00115	CcSEcCtD
Levobunolol—Headache—Epirubicin—pancreatic cancer	0.000929	0.00114	CcSEcCtD
Levobunolol—Dizziness—Doxorubicin—pancreatic cancer	0.000907	0.00111	CcSEcCtD
Levobunolol—Nausea—Epirubicin—pancreatic cancer	0.000881	0.00108	CcSEcCtD
Levobunolol—Headache—Doxorubicin—pancreatic cancer	0.00086	0.00105	CcSEcCtD
Levobunolol—Nausea—Doxorubicin—pancreatic cancer	0.000815	0.001	CcSEcCtD
Levobunolol—ADRB1—Signaling Pathways—GDI1—pancreatic cancer	0.000603	0.00327	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000603	0.00327	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000591	0.0032	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GDI1—pancreatic cancer	0.00059	0.0032	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GDI2—pancreatic cancer	0.00059	0.0032	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PPY—pancreatic cancer	0.000579	0.00314	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000578	0.00313	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—SST—pancreatic cancer	0.000573	0.0031	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000569	0.00308	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PPY—pancreatic cancer	0.000567	0.00307	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—SST—pancreatic cancer	0.00056	0.00304	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—SSTR3—pancreatic cancer	0.00056	0.00303	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000556	0.00301	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000549	0.00298	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—SSTR3—pancreatic cancer	0.000547	0.00297	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000537	0.00291	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—SSTR1—pancreatic cancer	0.000537	0.00291	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CNR1—pancreatic cancer	0.000529	0.00286	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PPY—pancreatic cancer	0.000526	0.00285	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—SSTR1—pancreatic cancer	0.000525	0.00284	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CNR1—pancreatic cancer	0.000517	0.0028	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—SSTR2—pancreatic cancer	0.000516	0.0028	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PPY—pancreatic cancer	0.000515	0.00279	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—GCG—pancreatic cancer	0.000511	0.00277	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—SSTR2—pancreatic cancer	0.000505	0.00274	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—GCG—pancreatic cancer	0.000499	0.00271	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCKBR—pancreatic cancer	0.000499	0.0027	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCKBR—pancreatic cancer	0.000488	0.00264	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—AGTR1—pancreatic cancer	0.000487	0.00264	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—AGTR1—pancreatic cancer	0.000476	0.00258	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—GAST—pancreatic cancer	0.000472	0.00256	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—GAST—pancreatic cancer	0.000462	0.0025	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—SCT—pancreatic cancer	0.000448	0.00243	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—SCT—pancreatic cancer	0.000438	0.00237	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—GAST—pancreatic cancer	0.000429	0.00232	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CCK—pancreatic cancer	0.000427	0.00231	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—GAST—pancreatic cancer	0.00042	0.00227	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CCK—pancreatic cancer	0.000418	0.00226	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000416	0.00225	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CNR2—pancreatic cancer	0.000416	0.00225	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00041	0.00222	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CNR2—pancreatic cancer	0.000407	0.00221	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000407	0.00221	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—SCT—pancreatic cancer	0.000407	0.0022	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000401	0.00217	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—SCT—pancreatic cancer	0.000398	0.00215	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRLHR—pancreatic cancer	0.000389	0.00211	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCK—pancreatic cancer	0.000388	0.0021	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRLHR—pancreatic cancer	0.00038	0.00206	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCK—pancreatic cancer	0.000379	0.00206	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CNR2—pancreatic cancer	0.000378	0.00205	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—GLP1R—pancreatic cancer	0.000378	0.00205	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CCKAR—pancreatic cancer	0.000372	0.00201	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CNR2—pancreatic cancer	0.00037	0.002	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—GLP1R—pancreatic cancer	0.00037	0.002	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—IAPP—pancreatic cancer	0.000369	0.002	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ACVR1B—pancreatic cancer	0.000366	0.00198	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ZNRF3—pancreatic cancer	0.000366	0.00198	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CCKAR—pancreatic cancer	0.000364	0.00197	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—IAPP—pancreatic cancer	0.000361	0.00195	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ZNRF3—pancreatic cancer	0.000358	0.00194	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ACVR1B—pancreatic cancer	0.000358	0.00194	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000354	0.00192	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000346	0.00188	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—SHH—pancreatic cancer	0.000339	0.00184	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IAPP—pancreatic cancer	0.000335	0.00181	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—SHH—pancreatic cancer	0.000332	0.0018	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—DTX1—pancreatic cancer	0.000331	0.00179	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SSTR3—pancreatic cancer	0.000331	0.00179	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IAPP—pancreatic cancer	0.000328	0.00177	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—SST—pancreatic cancer	0.000324	0.00175	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SSTR3—pancreatic cancer	0.000323	0.00175	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—DTX1—pancreatic cancer	0.000323	0.00175	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PTHLH—pancreatic cancer	0.000321	0.00174	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PTCH1—pancreatic cancer	0.000321	0.00174	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SSTR1—pancreatic cancer	0.000317	0.00172	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—SST—pancreatic cancer	0.000317	0.00172	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PTCH1—pancreatic cancer	0.000314	0.0017	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PTHLH—pancreatic cancer	0.000314	0.0017	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PPY—pancreatic cancer	0.000311	0.00168	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SSTR1—pancreatic cancer	0.00031	0.00168	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SSTR2—pancreatic cancer	0.000305	0.00165	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PPY—pancreatic cancer	0.000304	0.00165	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CNR1—pancreatic cancer	0.000299	0.00162	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SSTR2—pancreatic cancer	0.000298	0.00162	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCKBR—pancreatic cancer	0.000295	0.0016	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—SST—pancreatic cancer	0.000294	0.00159	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000293	0.00159	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CNR1—pancreatic cancer	0.000292	0.00158	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—GCG—pancreatic cancer	0.000289	0.00156	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCKBR—pancreatic cancer	0.000288	0.00156	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—SST—pancreatic cancer	0.000288	0.00156	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000287	0.00155	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—GCG—pancreatic cancer	0.000282	0.00153	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—DTX4—pancreatic cancer	0.000277	0.0015	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GLI1—pancreatic cancer	0.000277	0.0015	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000275	0.00149	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CNR1—pancreatic cancer	0.000271	0.00147	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GLI1—pancreatic cancer	0.000271	0.00147	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—DTX4—pancreatic cancer	0.000271	0.00147	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.00027	0.00146	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NRP1—pancreatic cancer	0.00027	0.00146	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000269	0.00146	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CNR1—pancreatic cancer	0.000265	0.00144	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000264	0.00143	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NRP1—pancreatic cancer	0.000264	0.00143	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—GCG—pancreatic cancer	0.000262	0.00142	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HEY2—pancreatic cancer	0.000259	0.00141	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—GCG—pancreatic cancer	0.000256	0.00139	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HEY2—pancreatic cancer	0.000254	0.00137	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GAST—pancreatic cancer	0.000253	0.00137	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AGTR1—pancreatic cancer	0.00025	0.00135	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GAST—pancreatic cancer	0.000248	0.00134	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AGTR1—pancreatic cancer	0.000245	0.00132	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SCT—pancreatic cancer	0.00024	0.0013	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HEY1—pancreatic cancer	0.00024	0.0013	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SCT—pancreatic cancer	0.000235	0.00127	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HEY1—pancreatic cancer	0.000235	0.00127	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCK—pancreatic cancer	0.000229	0.00124	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCK—pancreatic cancer	0.000224	0.00121	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CNR2—pancreatic cancer	0.000223	0.00121	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GLP1R—pancreatic cancer	0.000223	0.00121	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CXCL8—pancreatic cancer	0.000223	0.00121	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCKAR—pancreatic cancer	0.00022	0.00119	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GLP1R—pancreatic cancer	0.000218	0.00118	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CNR2—pancreatic cancer	0.000218	0.00118	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CXCL8—pancreatic cancer	0.000218	0.00118	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCKAR—pancreatic cancer	0.000215	0.00116	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—JAG2—pancreatic cancer	0.000213	0.00115	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MEN1—pancreatic cancer	0.00021	0.00114	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—JAG2—pancreatic cancer	0.000208	0.00113	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MEN1—pancreatic cancer	0.000205	0.00111	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SHH—pancreatic cancer	0.0002	0.00108	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NOTCH4—pancreatic cancer	0.000199	0.00108	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IAPP—pancreatic cancer	0.000198	0.00107	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SHH—pancreatic cancer	0.000196	0.00106	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NOTCH4—pancreatic cancer	0.000195	0.00105	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IAPP—pancreatic cancer	0.000194	0.00105	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTHLH—pancreatic cancer	0.00019	0.00103	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTCH1—pancreatic cancer	0.00019	0.00103	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTHLH—pancreatic cancer	0.000186	0.00101	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTCH1—pancreatic cancer	0.000186	0.00101	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SST—pancreatic cancer	0.000174	0.000941	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000171	0.000928	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—JAG1—pancreatic cancer	0.00017	0.000921	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SST—pancreatic cancer	0.00017	0.00092	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NOTCH3—pancreatic cancer	0.000169	0.000917	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000168	0.000908	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—JAG1—pancreatic cancer	0.000166	0.000901	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NOTCH3—pancreatic cancer	0.000166	0.000897	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CNR1—pancreatic cancer	0.00016	0.000868	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CNR1—pancreatic cancer	0.000157	0.000849	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000156	0.000843	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GCG—pancreatic cancer	0.000155	0.000838	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000152	0.000824	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GCG—pancreatic cancer	0.000151	0.00082	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000151	0.000816	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AGTR1—pancreatic cancer	0.000148	0.0008	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000147	0.000798	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STK11—pancreatic cancer	0.000146	0.000788	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AGTR1—pancreatic cancer	0.000144	0.000782	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STK11—pancreatic cancer	0.000142	0.000771	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000137	0.000741	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000134	0.000725	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000131	0.000711	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000128	0.000695	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SMAD4—pancreatic cancer	0.000127	0.00069	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000126	0.000683	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SMAD4—pancreatic cancer	0.000125	0.000675	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HES1—pancreatic cancer	0.000124	0.000674	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000123	0.000668	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HES1—pancreatic cancer	0.000122	0.000659	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000119	0.000646	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000117	0.000632	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000115	0.00062	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	0.000112	0.000607	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TERT—pancreatic cancer	0.000109	0.000591	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TERT—pancreatic cancer	0.000107	0.000578	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	0.000104	0.000565	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	0.000104	0.000564	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	0.000102	0.000553	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APOE—pancreatic cancer	0.000102	0.000552	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	0.000102	0.000551	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	9.97e-05	0.00054	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	9.96e-05	0.000539	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	9.76e-05	0.000529	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	9.49e-05	0.000514	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	9.4e-05	0.000509	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	9.28e-05	0.000503	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	9.19e-05	0.000498	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	9.19e-05	0.000498	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	9.19e-05	0.000498	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	9.08e-05	0.000492	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	8.99e-05	0.000487	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	8.99e-05	0.000487	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	8.88e-05	0.000481	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	8.37e-05	0.000453	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	8.19e-05	0.000444	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	8.08e-05	0.000438	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	8e-05	0.000433	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	7.91e-05	0.000428	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	7.9e-05	0.000428	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.83e-05	0.000424	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	7.74e-05	0.000419	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.27e-05	0.000394	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	7.11e-05	0.000385	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	7.04e-05	0.000381	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	6.89e-05	0.000373	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	6.77e-05	0.000366	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	6.72e-05	0.000364	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	6.62e-05	0.000359	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	6.58e-05	0.000356	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	6.54e-05	0.000354	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	6.48e-05	0.000351	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	6.39e-05	0.000346	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	6.33e-05	0.000343	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	6.3e-05	0.000341	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	6.24e-05	0.000338	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	6.17e-05	0.000334	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	6.12e-05	0.000331	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	6.11e-05	0.000331	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	6.08e-05	0.00033	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	5.99e-05	0.000324	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	5.95e-05	0.000322	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	5.94e-05	0.000322	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	5.81e-05	0.000315	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	5.64e-05	0.000306	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	5.52e-05	0.000299	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	5.5e-05	0.000298	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	5.44e-05	0.000295	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	5.43e-05	0.000294	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	5.38e-05	0.000291	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	5.32e-05	0.000288	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	5.31e-05	0.000288	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	5.06e-05	0.000274	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	5.04e-05	0.000273	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	4.95e-05	0.000268	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	4.95e-05	0.000268	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	4.93e-05	0.000267	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	4.84e-05	0.000262	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	4.67e-05	0.000253	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	4.57e-05	0.000248	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	4.29e-05	0.000232	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	4.2e-05	0.000227	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	4.15e-05	0.000225	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	4.06e-05	0.00022	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	3.97e-05	0.000215	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	3.88e-05	0.00021	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	3.51e-05	0.00019	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	3.43e-05	0.000186	CbGpPWpGaD
